# TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma

> **NCT04490694** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT04490694
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2021-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04490694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04490694, "TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04490694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*